National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/17405

TDMS Study 99035-01 Pathology Tables

NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04
Route: GAVAGE                                                                                                     Time: 12:54:57

                                                            FINAL #1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  556-52-5

       Lock Date:  09/24/01

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15                        
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 2            1            2            1            4                        
    Natural Death                                                                1                         2                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                13           14           12           14            9                        
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15                        
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                                     1 (7%)                                
   Intestine Large, Rectum                            (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                                                  1 (7%)                   
   Intestine Small, Duodenum                          (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        4 (27%)      1 (7%)       1 (7%)                   
   Intestine Small, Jejunum                           (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           3 (20%)      3 (20%)      1 (7%)                                
   Intestine Small, Ileum                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           2 (13%)      2 (13%)      1 (7%)       1 (7%)                   
   Liver                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              5 (33%)      1 (7%)       8 (53%)      5 (33%)      8 (53%)                  
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (7%)                                                          
   Mesentery                                                                    (2)                                                 
      Histiocytic Sarcoma                                                        2 (100%)                                           
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)                    1 (7%)                                
      Squamous Cell Papilloma                                                                 1 (7%)       3 (20%)                  
   Stomach, Glandular                                 (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       1 (7%)       2 (13%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       2 (13%)      2 (13%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              3 (20%)                   7 (47%)      2 (13%)      1 (7%)                   
   Adrenal Medulla                                    (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)                                                                       
   Pituitary Gland                                    (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)                    2 (13%)      1 (7%)       1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              8 (53%)      5 (33%)      8 (53%)      6 (40%)      5 (33%)                  
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (7%)                                                          
   Uterus                                             (15)         (15)         (15)         (15)         (15)                      
      Hemangiosarcoma, Metastatic, Spleen                                        1 (7%)                                             
      Histiocytic Sarcoma                                                        4 (27%)      4 (27%)      5 (33%)                  
      Sarcoma Stromal                                                                                      1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (15)         (15)         (15)         (15)         (15)                      
      Hemangiosarcoma                                                                         1 (7%)                                
      Histiocytic Sarcoma                              9 (60%)      8 (53%)     11 (73%)      8 (53%)      8 (53%)                  
   Lymph Node                                         (13)         (15)         (15)         (13)         (14)                      
      Lumbar, Histiocytic Sarcoma                                   2 (13%)      1 (7%)                    2 (14%)                  
      Mediastinal, Histiocytic Sarcoma                 1 (8%)       1 (7%)       6 (40%)      3 (23%)      3 (21%)                  
      Pancreatic, Histiocytic Sarcoma                                            1 (7%)                                             
      Renal, Histiocytic Sarcoma                                    2 (13%)                                1 (7%)                   
   Lymph Node, Mandibular                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       6 (40%)      2 (13%)      3 (20%)                  
   Lymph Node, Mesenteric                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              3 (20%)      3 (20%)      5 (33%)      3 (20%)      5 (33%)                  
   Spleen                                             (15)         (15)         (15)         (15)         (15)                      
      Hemangiosarcoma                                                            1 (7%)                                             
      Histiocytic Sarcoma                              2 (13%)      2 (13%)      7 (47%)      3 (20%)      2 (13%)                  
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - cont                                                                                                         
   Thymus                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       6 (40%)      2 (13%)      2 (13%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)                      
      Subcutaneous Tissue, Hemangiosarcoma             1 (7%)                                                                       
      Subcutaneous Tissue, Histiocytic Sarcoma                                   2 (13%)                   1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                                                                        (2)                       
      Histiocytic Sarcoma                                                                                  2 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (15)         (15)         (15)         (15)         (15)                      
      Choristoma                                                                                           1 (7%)                   
      Histiocytic Sarcoma                              1 (7%)                    4 (27%)      4 (27%)      2 (13%)                  
   Spinal Cord                                                                                            (1)                       
      Histiocytic Sarcoma                                                                                  1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)                      
      Alveolar/Bronchiolar Adenoma                                  1 (7%)                    1 (7%)       4 (27%)                  
      Alveolar/Bronchiolar Carcinoma                                                          1 (7%)                                
      Histiocytic Sarcoma                              2 (13%)                   6 (40%)      3 (20%)      6 (40%)                  
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (7%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Zymbal's Gland                                                                            (1)          (1)                       
      Squamous Cell Carcinoma                                                                              1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)                    4 (27%)      2 (13%)      3 (20%)                  
   Urinary Bladder                                    (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        2 (13%)      2 (13%)      2 (13%)                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)                      
      Histiocytic Sarcoma                              9 (60%)      9 (60%)     12 (80%)     10 (67%)     13 (87%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            10           9          12          12          14                           
     Total Primary Neoplasms                           10          10          13          14          23                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                              1                       2           7                           
     Total Benign Neoplasms                                         1                       2           7                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms              10           9          12          11          14                           
     Total Malignant Neoplasms                         10           9          13          12          15                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                          1           1                                                   
     Total Metastatic Neoplasm                                      3           1                                                   
                                                                                                                                    
   Total Animals with Malignant Neoplasms                           1                                                               
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                  1                           
     Total Uncertain Neoplasms                                                                          1                           
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15                        
  Early Deaths                                                                                                                      
    Natural Death                                      2            1            1            1            3                        
    Moribund Sacrifice                                                           1                         4                        
    Dosing Accident                                                                                        1                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                13           14           13           14            7                        
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15                        
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Rectum                            (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        1 (7%)                    1 (7%)                   
   Intestine Large, Cecum                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        1 (7%)                                             
   Intestine Small, Duodenum                          (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        1 (7%)                    2 (13%)                  
   Intestine Small, Jejunum                           (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        2 (13%)      1 (7%)                                
   Intestine Small, Ileum                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                                                  1 (7%)                   
   Liver                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              2 (13%)      2 (13%)      4 (27%)      2 (13%)     10 (67%)                  
   Pancreas                                                                                               (1)                       
      Histiocytic Sarcoma                                                                                  1 (100%)                 
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)                      
      Squamous Cell Papilloma, Multiple                                                                    1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)                                 5 (33%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (15)         (15)         (15)         (14)         (15)                      
      Histiocytic Sarcoma                                                                     1 (7%)       1 (7%)                   
   Pituitary Gland                                    (15)         (15)         (14)         (15)         (15)                      
      Histiocytic Sarcoma                                                                                  1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Epididymis                                         (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                                     2 (13%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              2 (13%)      5 (33%)      6 (40%)      4 (27%)      8 (53%)                  
   Lymph Node                                         (14)         (14)         (15)         (13)         (13)                      
      Mediastinal, Histiocytic Sarcoma                              1 (7%)       3 (20%)                   7 (54%)                  
      Mediastinal, Osteosarcoma, Metastatic, Skin      1 (7%)                                                                       
   Lymph Node, Mandibular                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       2 (13%)                   3 (20%)                  
   Lymph Node, Mesenteric                             (15)         (15)         (15)         (14)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       2 (13%)      1 (7%)       5 (33%)                  
   Spleen                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       3 (20%)      1 (7%)       7 (47%)                  
   Thymus                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       2 (13%)      2 (13%)      4 (27%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)                      
      Osteosarcoma                                     1 (7%)                                                                       
      Squamous Cell Papilloma                                       1 (7%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                                                           (1)                                    
      Hemangiosarcoma                                                                         1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       1 (7%)       1 (7%)       4 (27%)                  
   Spinal Cord                                                                               (1)                                    
      Histiocytic Sarcoma                                                                     1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)                      
      Alveolar/Bronchiolar Adenoma                     1 (7%)                    2 (13%)      5 (33%)      2 (13%)                  
      Alveolar/Bronchiolar Adenoma, Multiple                                                  2 (13%)      1 (7%)                   
      Alveolar/Bronchiolar Carcinoma                   2 (13%)                   1 (7%)       3 (20%)                               
      Alveolar/Bronchiolar Carcinoma, Multiple                      1 (7%)                                                          
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       2 (13%)      2 (13%)      6 (40%)                  
      Osteosarcoma, Metastatic, Skin                   1 (7%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                                 (1)                                                              
      Adenoma                                                       1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       2 (13%)      2 (13%)      5 (33%)                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)                      
      Histiocytic Sarcoma                              2 (13%)      6 (40%)      9 (60%)      5 (33%)     11 (73%)                  
      Lymphoma Malignant                               2 (13%)                                1 (7%)                                
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 SYSTEMIC LESIONS - cont                                                                                                            
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             7           8          12          12          12                           
     Total Primary Neoplasms                            8           9          12          17          15                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                  1           2           2           7           4                           
     Total Benign Neoplasms                             1           2           2           7           4                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms               6           7          10           9          11                           
     Total Malignant Neoplasms                          7           7          10          10          11                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              1                                                                           
     Total Metastatic Neoplasm                          2                                                                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------                                           
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.